陸燕,何清,劉沙
布洛芬對(duì)偏頭痛大鼠模型三叉神經(jīng)節(jié)神經(jīng)元電壓門控型鈣通道的影響
陸燕1,何清1,劉沙2
目的:探討布洛芬對(duì)偏頭痛大鼠模型三叉神經(jīng)節(jié)神經(jīng)元高電壓激活鈣通道電流(HVA-ICa)的調(diào)控作用。方法:雄性SD大鼠24只隨機(jī)分為3組:生理鹽水(NS)組、致炎劑(IS)+降鈣素基因相關(guān)肽(CGRP)(IS+ CGRP)組和布洛芬組,各8只。采用新型IS構(gòu)建偏頭痛大鼠模型,全細(xì)胞式膜片鉗技術(shù)記錄急性分離的三叉神經(jīng)節(jié)神經(jīng)元鈣電流(HVA-ICa)。結(jié)果:與NS組相比較,(IS+CGRP)組HVA-ICa峰值密度增高,激活電壓向超級(jí)化方向移動(dòng)(P<0.05);與(IS+CGRP)組相比,布洛芬組鈣電流峰電流降低(P<0.05)。與NS組相比,(IS+CGRP)組半數(shù)激活電壓向超級(jí)化方向移動(dòng)(P<0.05);與(IS+CGRP)組相比,布洛芬組半數(shù)激活電壓向去級(jí)化方向移動(dòng)(P<0.05)。與NS組相比,(IS+CGRP)組半數(shù)失活電壓向去級(jí)化方向移動(dòng)(P<0.05);與(IS+CGRP)組相比,布洛芬組半數(shù)失活電壓向超級(jí)化方向移動(dòng)(P<0.05)。結(jié)論:布洛芬能夠降低三叉神經(jīng)節(jié)神經(jīng)元HVA-ICa的幅度、促進(jìn)HVA-ICa的失活。
偏頭痛;三叉神經(jīng)節(jié);鈣通道;布洛芬
偏頭痛是一種常見的反復(fù)發(fā)作性的腦功能異常疾病,表現(xiàn)為單側(cè)或雙側(cè)的搏動(dòng)性頭痛,可伴有畏光或畏聲等先兆癥狀,一般持續(xù)3~72 h,休息可緩解頭痛的發(fā)作[1]。目前,偏頭痛的發(fā)病機(jī)制尚未明確,主要包括兩大學(xué)說:皮質(zhì)擴(kuò)散性抑制學(xué)說(cortical spreading depress,CSD)和三叉神經(jīng)血管學(xué)說[2]。既往研究提示:先兆的發(fā)生和CSD有關(guān),而偏頭痛的發(fā)作是三叉神經(jīng)血管系統(tǒng)(trigeminovascular system,TGVS)激活所導(dǎo)致[2]。TGVS被激活后,P物質(zhì)(substance P,SP)、降鈣素基因相關(guān)肽(calcitonin gene related peptide,CGRP)和神經(jīng)肽A(neurokinin A,NKA)等神經(jīng)遞質(zhì)從三叉神經(jīng)末梢中釋放,造成硬腦膜血管擴(kuò)張、血管內(nèi)血漿外滲、血小板激活以及肥大細(xì)胞脫顆粒,誘發(fā)腦膜神經(jīng)源性炎癥反應(yīng),導(dǎo)致頭痛的發(fā)作[3]。
電壓門控型鈣離子通道(voltage-gated calcium channel,VGCC)在神經(jīng)遞質(zhì)釋放以及超極化的復(fù)極化過程起重要作用,其特性改變影響神經(jīng)元的興奮性和活性[4]。在TGVS中,VGCC通過調(diào)節(jié)中小三叉神經(jīng)節(jié)神經(jīng)元上Aδ纖維和C纖維的興奮性,影響神經(jīng)末梢CGRP的釋放,同時(shí)參與疼痛信號(hào)的傳遞[5]。Xiao等[6]發(fā)現(xiàn)三叉神經(jīng)節(jié)神經(jīng)元上的VGCC參與調(diào)節(jié)高KCl誘導(dǎo)的CGRP釋放,而鈣通道阻滯劑能抑制該現(xiàn)象發(fā)生。非甾體類抗炎藥布洛芬(Ibuprofen)主要通過抑制中樞及外周神經(jīng)系統(tǒng)中前列腺素E的合成來發(fā)揮鎮(zhèn)痛作用,在偏頭痛急性期廣泛應(yīng)用[7,8]。
本實(shí)驗(yàn)采用新型復(fù)方化學(xué)致炎劑(inflammatory soup,IS)+CGRP刺激大鼠硬腦膜,成功構(gòu)建偏頭痛大鼠模型。通過觀察硬腦膜神經(jīng)末梢敏化對(duì)三叉神經(jīng)節(jié)神經(jīng)元細(xì)胞上高電壓激活鈣通道電流(high voltage activated calcium current,HVA-ICa)的影響,以及布洛芬對(duì)偏頭痛大鼠模型中HVA-ICa的作用,初步探討布洛芬對(duì)VGCC的調(diào)控作用,為研究布洛芬緩解偏頭痛發(fā)作的機(jī)制提供依據(jù)。
1.1 材料
1.1.1 實(shí)驗(yàn)動(dòng)物 清潔級(jí)SD雄性大鼠24只,體質(zhì)量250~300 g,由徐州醫(yī)學(xué)院實(shí)驗(yàn)動(dòng)物中心提供。飼養(yǎng)于徐州醫(yī)學(xué)院實(shí)驗(yàn)動(dòng)物中心,室溫21℃~25℃,相對(duì)濕度約50%,12 h白天/黑夜循環(huán)控制。
1.1.2 主要試劑與材料 NaCl、MgCl2、CaCl2、D-glucose、NaOH、KCl、KH2PO4、NaHCO3、Na2HPO4、布洛芬、CsF、EGTA、谷氨酰胺、HEPES、Na-ATP、TEA-Cl、膠原酶I型、Mg-ATP、Li-GTP、CsOH、胰酶、5-羥色胺、組胺、緩激肽、前列腺素E2均購自美國Sigma公司;10%水合氯醛、羥乙基哌嗪乙磺酸為國產(chǎn)分析純。
1.2 方法
1.2.1 分組、偏頭痛大鼠模型的建立及硬腦膜給藥 按照隨機(jī)法將大鼠分為生理鹽水(normal saline,NS)組、(IS+CGRP)組、布洛芬組,各8只。10%水合氯醛0.4 mL/100 g腹腔注射麻醉大鼠,立體定位儀固定頭部,暴露顱骨。定位于后囟點(diǎn),鉆開顱骨,充分暴露上矢狀竇(superior sagittal sinus,SSS)。將PE-10軟管置入SSS,并完全固定。術(shù)后第4天通過PE-10軟管給予藥物。NS組給予20 μL NS;(IS+CGRP)組給予10 μL IS(包含 2 mmol/L 5-羥色胺、緩激肽、組胺和0.2 mmol/L前列腺素E2)+10 μLCGRP(10-4mol/L)[9,10];布洛芬組先給予布洛芬混懸液(27 mg/kg)灌胃,1 h后通過PE-10軟管給予10 μL IS+10 μL CGRP。
1.2.2 三叉神經(jīng)節(jié)神經(jīng)元急性分離 各組大鼠給藥1 h后,斷頭去除腦組織,將顱底一對(duì)三叉神經(jīng)節(jié)取出置于Hank’s平衡溶液中洗凈,轉(zhuǎn)入含有1.5 mg/mL胰酶和0.5 mg/mLI型膠原酶中,37℃水浴消化15~20 min,標(biāo)準(zhǔn)外液洗3遍,巴斯德管吹打至神經(jīng)節(jié)分散,200目濾網(wǎng)過濾并轉(zhuǎn)移至35 mm培養(yǎng)皿中,放置于孵箱,貼壁6 h后進(jìn)行全細(xì)胞膜片鉗實(shí)驗(yàn)。
1.2.3 全細(xì)胞膜片鉗記錄 選用細(xì)胞膜清晰、軸突完整的中小三叉神經(jīng)節(jié)神經(jīng)元進(jìn)行實(shí)驗(yàn)。EPC-10膜片鉗放大器記錄,pulse+pulsefit程序(德國HEKA公司)進(jìn)行電流的記錄。電極入液后,與細(xì)胞形成高阻抗封接(>1 GΩ),負(fù)壓破膜,同時(shí)補(bǔ)償慢電容(Cs)和局部串聯(lián)電阻(Rs)。將Rs<20 MΩ并且電流穩(wěn)定的數(shù)據(jù)視作有效。鉗制電壓為-60 mV,指令電壓為-50 mV~+30 mV,10 mV遞增,激活閾值為-40 mV,峰值電壓0 mV,并且可以被100 μmmol/L CdCl2完全阻斷,提示記錄到HVA-ICa電流,見圖1。
圖1 正常三叉神經(jīng)節(jié)神經(jīng)元高電壓激活鈣電流及I-V曲線
1.3 統(tǒng)計(jì)學(xué)處理
通過Clampfi軟件(美國Axon公司)處理電流曲線。采用SPSS 19.0軟件處理數(shù)據(jù),計(jì)量資料以(±s)表示,配對(duì)t檢驗(yàn),P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2.1 布洛芬對(duì)偏頭痛大鼠三叉神經(jīng)節(jié)神經(jīng)元HVA-ICa的抑制作用
峰值電流的激活電壓NS組為0 mV,(IS+CGRP)組向超級(jí)化方向移動(dòng)-10 mV。NS組、(IS+CGRP)組及布洛芬組的HVA-ICa峰電流分別為(-50.3±4.28)、(-80.21±3.96)及(-54.84±5.82)pA/pF;(IS+CGRP)組高于NS組(P<0.05),布洛芬組低于(IS+CGRP)組(P<0.05),見圖2。
圖2 布洛芬對(duì)偏頭痛大鼠三叉神經(jīng)節(jié)神經(jīng)元鈣電流的抑制作用
2.2 布洛芬對(duì)偏頭痛大鼠三叉神經(jīng)節(jié)神經(jīng)元HVA-ICa激活曲線的影響
NS組、(IS+CGRP)組及布洛芬組HVA-ICa的半數(shù)激活電壓(Va1/2)分別為(-17.3±0.5)、(-21.5±0.4)及(-18.9±1.5)mV;(IS+CGRP)組激活曲線較NS組向超級(jí)化方向移動(dòng)4.2 mV,差異有統(tǒng)計(jì)學(xué)意義(P<0.05),布洛芬組激活曲線較(IS+CGRP)組向去級(jí)化方向移動(dòng)2.4 mV,差異有統(tǒng)計(jì)學(xué)意義(P<0.05),見圖3。
2.3 布洛芬對(duì)偏頭痛大鼠三叉神經(jīng)節(jié)神經(jīng)元HVA-ICa失活曲線的影響
NS組、(IS+CGRP)組及布洛芬組HVA-ICa的半數(shù)失活電壓(Vi1/2)分別為(-24.8±0.5)、(-13.6±0.4)及(-17.9±2.0)mV;(IS+CGRP)組失活曲線較NS組向去極化方向移動(dòng)11.2 mV,差異有統(tǒng)計(jì)學(xué)意義(P<0.05),布洛芬組失活曲線較(IS+CGRP)組向超級(jí)化方向移動(dòng)了4.3 mV,差異有統(tǒng)計(jì)學(xué)意義(P<0.05),見圖4。
圖3 布洛芬對(duì)偏頭痛大鼠三叉神經(jīng)節(jié)神經(jīng)元鈣電流激活曲線的影響
圖4 布洛芬對(duì)偏頭痛大鼠三叉神經(jīng)節(jié)神經(jīng)元鈣電流失活曲線的影響
偏頭痛發(fā)作時(shí),硬腦膜血管擴(kuò)張和神經(jīng)源性炎癥通過刺激硬腦膜及血管周圍的痛覺感受器,造成三叉神經(jīng)元興奮,并將痛覺信號(hào)上傳至大腦皮質(zhì),產(chǎn)生頭痛;同時(shí),三叉神經(jīng)末梢釋放神經(jīng)源性遞質(zhì),如SP、CGRP和NKA等[11]。疼痛敏感組織受到刺激,Tenascin-C(TNC)細(xì)胞興奮和激活,再次釋放血管活性物質(zhì),造成腦膜的無菌性炎癥反應(yīng),導(dǎo)致血管擴(kuò)張,延長(zhǎng)頭痛的發(fā)作時(shí)間,增加頭痛的程度[12]。偏頭痛發(fā)作時(shí),CGRP被釋放至頸內(nèi)和頸外的靜脈血[13]。在無先兆偏頭痛患者的外周血中能檢測(cè)到CGRP水平增高;給予偏頭痛發(fā)作期患者舒馬普曲坦治療后,頸靜脈血CGRP水平降至正常[13,14]。外源性給予患者CGRP,同樣可誘發(fā)偏頭痛樣癥狀發(fā)作。CGRP可引起腦膜動(dòng)脈擴(kuò)張,促使肥大細(xì)胞脫顆粒、釋放組胺,從而參與神經(jīng)源性炎癥反應(yīng)[15,16]。感覺神經(jīng)末梢激活后,CGRP和SP釋放,刺激腦膜傷害感受器,通過正反饋調(diào)節(jié)作用,延長(zhǎng)頭痛發(fā)作的時(shí)間[16,17]。肥大細(xì)胞脫顆粒能激活硬腦膜上的C纖維和Aδ纖維,并激活三叉神經(jīng)脊束核,將疼痛信號(hào)向丘腦和皮質(zhì)傳遞[18]。IS是多種化學(xué)炎性刺激物的混合物。向大鼠延髓池注入IS能引起TGVS激活,促進(jìn)CGRP釋放,同時(shí)還造成大鼠前爪皮下肥大細(xì)胞脫顆粒,降低大鼠的痛覺閾值[9,19]。硬腦膜傷害感受器反復(fù)激活會(huì)造成中樞和外周神經(jīng)系統(tǒng)功能和形態(tài)的改變,使痛覺閾值降低,產(chǎn)生痛覺敏化。在大鼠硬腦膜處放置PE-10管,清醒狀態(tài)下給予IS,造成TGVS的反復(fù)激活,能較為完善地模擬三叉神經(jīng)血管反射學(xué)說的病理生理過程。
VGCC的激活與神經(jīng)遞質(zhì)的釋放及神經(jīng)元興奮性有密切關(guān)聯(lián)[20]。阻滯電壓門控型鈣通道可顯著減少神經(jīng)末梢CGRP的釋放[21,22]。培養(yǎng)三叉神經(jīng)節(jié)神經(jīng)元,發(fā)現(xiàn)CGRP表達(dá)量與VGCC的表達(dá)量呈正相關(guān);與其他細(xì)胞相比,CGRP和VGCC有共表達(dá)的神經(jīng)元,其軸突數(shù)量和密度也增加[23]。本實(shí)驗(yàn)發(fā)現(xiàn):與NS組相比較,IS+CGRP組HVA-ICa峰電流密度增高,并具有電壓依賴性;IS+CGRP組的HVA-ICa激活曲線向超級(jí)化方向移動(dòng),提示VGCC對(duì)電壓改變的敏感性增強(qiáng),細(xì)胞膜興奮性增高,通道容易激活;同時(shí)IS+CGRP組HVA-ICa的失活曲線向去極化方向移動(dòng),提示在外周敏化條件下,VGCC的失活閾值增高,不易失活。
布洛芬為選擇性的COX-2抑制劑,通過抑制前列腺素和其他神經(jīng)炎性介質(zhì)合成,減輕局部組織炎癥反應(yīng),降低局部神經(jīng)的痛覺敏感性,發(fā)揮鎮(zhèn)痛作用[24,25]。在本實(shí)驗(yàn)中,與IS+CGRP組相比較,布洛芬能抑制硬腦膜傳入神經(jīng)末梢激活導(dǎo)致的HVA-ICa增高,并且具有電壓依賴性;布洛芬組的HVA-ICa激活曲線向去極化方向移動(dòng),提示VGCC對(duì)電壓改變的敏感性降低,不易被激活,細(xì)胞膜興奮性降低;同時(shí)布洛芬組的HVAICa失活曲線向超級(jí)化方向移動(dòng),提示布洛芬抑制VGCC的活性,并與失活的VGCC結(jié)合,使VGCC長(zhǎng)期處于穩(wěn)態(tài)失活狀態(tài)。布洛芬對(duì)VGCC的這種調(diào)控,使靜息條件下對(duì)去極化產(chǎn)生反應(yīng)的VGCC數(shù)量減少,三叉神經(jīng)節(jié)神經(jīng)元對(duì)外界刺激的敏感性降低,三叉神經(jīng)節(jié)神經(jīng)元興奮性降低,痛覺信號(hào)的傳遞受到抑制;同時(shí)布洛芬通過抑制三叉神經(jīng)節(jié)上VGCC的開放,減少突觸后膜神經(jīng)炎性遞質(zhì)的釋放,減輕神經(jīng)源性炎癥反應(yīng),緩解偏頭痛的發(fā)作。
綜上所述,本實(shí)驗(yàn)通過新型的IS構(gòu)建大鼠偏頭痛模型,對(duì)三叉神經(jīng)節(jié)神經(jīng)元的外周敏化過程進(jìn)行研究,為探討VGCC在偏頭痛信號(hào)傳遞過程中的作用提供了相關(guān)實(shí)驗(yàn)依據(jù)。
[1]李雯,徐恩.家族性偏癱性偏頭痛的研究進(jìn)展[J].神經(jīng)損傷與功能重建,2006,1:181-184.
[2]Pietrobon D,Moskowitz MA.Pathophysiology of migraine[J].Annu Rev Physiol,2013,75:365-391.
[3]Tajti J,Szok D,Majlath Z,et al.Migraine and neuropeptides[J].Neuro Peptides,2015,52:19-30.
[4]Pietrobon D.Calcium channels and migraine[J].Biochim Biophys Acta,2013,1828:1655-1665.
[5]Karsan N,Goadsby PJ.Calcitonin gene-related peptide and migraine [J].CurrOpinNeurol,2015,28:250-254.
[6]Xiao Y,Richter JA,Hurley JH.Release of glutamate and CGRP from trigeminal ganglion neurons:Role of calcium channels and 5-HT1 receptor signaling[J].Mol Pain,2008,4:12-22.
[7]Becker WJ.Acute Migraine Treatment[J].Continuum(MinneapMinn), 2015,21(4 Headache):953-972.
[8]Marmura MJ,Silberstein SD,Schwedt TJ.The acute treatment of migraine in adults:the american headache society evidence assessment of migraine pharmacotherapies[J].Headache,2015,55:3-20.
[9]Steen KH,Steen AE,Reeh PW.A dominant role of acid pH in inflammatory excitation and sensitization of nociceptors in rat skin,in vitro[J].J Neurosci,1995,15:3982-3989.
[10]Herbert MK,Holzer P.[Innovative treatment of acute migraine pain with CGRP receptor antagonists][J].Anasthesiol Intensivmed Notfallmed Schmerzther,2004,39:657-661.
[11]Noseda R,Burstein R.Migraine pathophysiology:anatomy of the trigeminovascular pathway and associated neurological symptoms,CSD,sensitization and modulation of pain[J].Pain,2013,154 Suppl 1:10.
[12]Boyer N,Dallel R,Artola A,et al.General trigeminospinal central sensitization and impaired descending pain inhibitory controls contribute to migraine progression[J].Pain,2014,155:1196-1205.
[13]Cernuda-Morollon E,Ramon C,Martinez-Camblor P,et al.OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine[J].Pain,2015,156:820-824.
[14]Eftekhari S,Warfvinge K,Blixt FW,et al.Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system[J].J Pain,2013,14:1289-1303.
[15]Labruijere S,Ibrahimi K,Chan KY,et al.Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies[J].Expert Opin Drug Discov,2013,8:1309-1323.
[16]Diener HC.CGRP as a new target in prevention and treatment of migraine[J].Lancet Neurol,2014,13:1065-1067.
[17]Russo AF.Calcitonin gene-related peptide(CGRP):a new target for migraine[J].Annu Rev PharmacolToxicol,2015,55:533-552.
[18]Levy D,Burstein R,Kainz V,et al.Mast cell degranulation activates a pain pathway underlying migraine headache[J].Pain,2007,130:166-176.
[19]Wieseler J,Ellis A,Sprunger D,et al.A novel method for modeling facial allodynia associated with migraine in awake and freely moving rats [J].J Neurosci Methods,2010,185:236-245.
[20]耿曉英.氟桂利嗪聯(lián)合血塞通治療偏頭痛的臨床療效觀察[J].神經(jīng)損傷與功能重建,2012,7:307-308.
[21]Amrutkar DV,Ploug KB,Olesen J,et al.Role for voltage gated calcium channels in calcitonin gene-related peptide release in the rat trigeminovascularsystem[J].Neurosci,2011,172:510-517.
[22]Baillie LD,Schmidhammer H,Mulligan SJ.Peripheral mu-opioid receptor mediated inhibition of calcium signaling and action potentialevoked calcium fluorescent transients in primary afferent CGRP nociceptive terminals[J].Neuropharmacology,2015,93:267-273.
[23]Kuris A,Xu CB,Zhou MF,et al.Enhanced expression of CGRP in rat trigeminal ganglion neurons during cell and organ culture[J].Brain Res, 2007,1173:6-13.
[24]Derry S,Karlin SM,Moore RA.Single dose oral ibuprofen plus codeine for acute postoperative pain in adults[J].Cochrane Database Syst Rev,2015,2:CD010107.
[25]Derry S,Moore RA,Gaskell H,et al.Topical NSAIDs for acute musculoskeletal pain in adults[J].Cochrane Database Syst Rev,2015,6: CD007402.
(本文編輯:王晶)
Effects of Ibuprofen on High Voltage Active Calcium Currents in Trigeminal Ganglion Neu-rons in Rat Model of Migraine
LU Yan1,HE Qing1,LIU Sha2.
1.Department of Neurology,the First People's Hospital of Xuzhou,Jiangsu 221000,China;2.Department of Neurology,Affiliated Hospital,Xuzhou Medical University,Jiangsu 221002,China
Objective:To investigate the effects of ibuprofen on high voltage active calcium currents(HVAICa)in trigeminal ganglion neurons in rat model of migraine.Methods:Twenty-four male adult SD rats were randomly divided into 3 groups(n=8 respectively):normal saline treatment(NS)group,IS+CGRP group and ibuprofen group.The migraine models were established by IS+CGRP,and changes of HVA-ICa of trigeminal ganglion neurons were recorded using whole-cell patch clamp technique.Results:The peak amplitude of HVA-ICa in (IS+CGRP)group was increased compared to NS group,and activation voltage was shifted to hyperpolarization (P<0.05).Ibuprofen inhibited the peak amplitude of HVA-ICa compared to(IS+CGRP)group(P<0.05).The half-activation voltage(Va1/2)in(IS+CGRP)group was shifted in the hyperpolarizing direction compared to NS group(P<0.05),and ibuprofen shifted Va1/2 in the depolarizing direction compared to(IS+CGRP)group(P<0.05).The steady-state inactivation curve in(IS+CGRP)group was shifted towards more depolarizing potentials compared to NS group(P<0.05),and ibuprofen shifted the half-inactivation voltage(Vi1/2)in the hyperpolarizing direction compared to(IS+CGRP)group(P<0.05).Conclusion:Ibuprofen can reduce the amplitude of HVA-ICa of trigeminal ganglion neurons,and promote the inactivation of HVA-ICa.
migraine;trigeminal ganglion;calcium channels;ibuprofen
R741;R741.05
ADOI10.16780/j.cnki.sjssgncj.2016.03.002
1.徐州市第一人民醫(yī)院神經(jīng)內(nèi)3科
江蘇 徐州 221000 2.徐州醫(yī)科大學(xué)附屬醫(yī)院神經(jīng)內(nèi)1科江蘇 徐州 221002
2015-09-04
劉沙
lululiusha@163. com